Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Pulmonary reperfusion injury in post-palliative intervention of oligaemic cyanotic CHD: a new catastrophic consequence or just revisiting the same old story?

View through CrossRef
AbstractPulmonary reperfusion injury is a well-recognised clinical entity in the setting pulmonary artery angioplasty for pulmonary artery stenosis or chronic thromboembolic disease, but not much is known about this complication in post-palliative intervention of oligaemic cyanotic CHD. The pathophysiology of pulmonary reperfusion injury in this population consists of both ischaemic and reperfusion injury, mainly resulting in oxidative stress from reactive oxygen species generation, followed by endothelial dysfunction, and cytokine storm that may induce multiple organ dysfunction. Other mechanisms of pulmonary reperfusion injury are “no-reflow” phenomenon, overcirculation from high pressure in pulmonary artery, and increased left ventricular end-diastolic pressure. Chronic hypoxia in cyanotic CHD eventually depletes endogenous antioxidant and increased the risk of pulmonary reperfusion injury, thus becoming a concern for palliative interventions in the oligaemic subgroup. The incidence of pulmonary reperfusion injury varies depending on multifactors. Despite its inconsistence occurrence, pulmonary reperfusion injury does occur and may lead to morbidity and mortality in this population. The current management of pulmonary reperfusion injury is supportive therapy to prevent deterioration of lung injury. Therefore, a general consensus on pulmonary reperfusion injury is necessary for the diagnosis and management of this complication as well as further studies to establish the use of novel and potential therapies for pulmonary reperfusion injury.
Title: Pulmonary reperfusion injury in post-palliative intervention of oligaemic cyanotic CHD: a new catastrophic consequence or just revisiting the same old story?
Description:
AbstractPulmonary reperfusion injury is a well-recognised clinical entity in the setting pulmonary artery angioplasty for pulmonary artery stenosis or chronic thromboembolic disease, but not much is known about this complication in post-palliative intervention of oligaemic cyanotic CHD.
The pathophysiology of pulmonary reperfusion injury in this population consists of both ischaemic and reperfusion injury, mainly resulting in oxidative stress from reactive oxygen species generation, followed by endothelial dysfunction, and cytokine storm that may induce multiple organ dysfunction.
Other mechanisms of pulmonary reperfusion injury are “no-reflow” phenomenon, overcirculation from high pressure in pulmonary artery, and increased left ventricular end-diastolic pressure.
Chronic hypoxia in cyanotic CHD eventually depletes endogenous antioxidant and increased the risk of pulmonary reperfusion injury, thus becoming a concern for palliative interventions in the oligaemic subgroup.
The incidence of pulmonary reperfusion injury varies depending on multifactors.
Despite its inconsistence occurrence, pulmonary reperfusion injury does occur and may lead to morbidity and mortality in this population.
The current management of pulmonary reperfusion injury is supportive therapy to prevent deterioration of lung injury.
Therefore, a general consensus on pulmonary reperfusion injury is necessary for the diagnosis and management of this complication as well as further studies to establish the use of novel and potential therapies for pulmonary reperfusion injury.

Related Results

Comparative growth outcomes in pediatric congenital heart disease: Analyzing the dichotomy between cyanotic and Acyanotic conditions
Comparative growth outcomes in pediatric congenital heart disease: Analyzing the dichotomy between cyanotic and Acyanotic conditions
Introduction: Congenital heart disease (CHD), the most common birth defect, significantly affects nearly 1% of newborns, influencing their growth and developmental trajectories. Al...
Black-White Differences in Incident Fatal, Nonfatal, and Total Coronary Heart Disease
Black-White Differences in Incident Fatal, Nonfatal, and Total Coronary Heart Disease
Background: Blacks have higher coronary heart disease (CHD) mortality compared with whites. However, a previous study suggests that nonfatal CHD risk may be lower for b...
Abstract MP07: Racial Differences in Incident CHD in Observational Population-based Studies
Abstract MP07: Racial Differences in Incident CHD in Observational Population-based Studies
Background: In the modern era, black men have twice the risk for fatal CHD versus white men, with similar incidence of total CHD. To examine secular trends in these fin...
Clinical features of COVID-19 patients with comorbid coronary heart disease
Clinical features of COVID-19 patients with comorbid coronary heart disease
Abstract Background: In addition to the lungs, the coronavirus disease 2019 (COVID-19) also affects multiple organs throughout the body. The relationship between COVID-19 i...
COVID‐19 in Cyanotic Congenital Heart Disease
COVID‐19 in Cyanotic Congenital Heart Disease
Congenital heart disease (CHD) is the most prevalent congenital defect in newborn infants. Due to the various types of heart abnormalities, CHD can have a wide range of symptoms. C...
Levels of apoA-I, apoA-IV and SAA both in plasma and high-density lipoprotein in coronary heart disease patients
Levels of apoA-I, apoA-IV and SAA both in plasma and high-density lipoprotein in coronary heart disease patients
Background In recent years, studies have shown that elevated level of HDL may not have a cardiovascular protective effect. Our study is to focus on the protein co...
THE PARAOXONASE L55M POLYMORPHISM IN PATIENTS WITH CORONARY HEART DISEASE IN CHINESE POPULATION
THE PARAOXONASE L55M POLYMORPHISM IN PATIENTS WITH CORONARY HEART DISEASE IN CHINESE POPULATION
Objectives To investigate the distribution of the L/M polymorphism of PON-1 gene in Chinese Han nationality and to analyse the association of PON-1 gene, serum PO...

Back to Top